Indaptus Therapeutics, Inc. (INDP) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Indaptus Therapeutics reported revenue of $0. Net income was -$20.8M, or -$21.58 per diluted share. Operating activities generated -$14.8M of cash, leaving -$14.8M of free cash flow. At fiscal year end, Indaptus Therapeutics held $9.3M in total assets against $6.2M in total liabilities, including $8.5M of cash and equivalents.
Open the full interactive Indaptus Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Indaptus Therapeutics Key Stats
| Share Price | $2.39 |
|---|---|
| Market Cap | $277.6M |
| 52-Week Range | $0.94 – $4.75 |
| Shares Outstanding | 116.1 million (basic, 2026 Q2) |
Indaptus Therapeutics Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$7.7M | -$14.9M | -$16.4M | -$15.4M | -$19.8M |
| Pre-Tax Income | -$7.7M | -$14.3M | -$15.4M | -$15.0M | -$20.8M |
| Income Tax | $1,650 | $30 | $2,450 | $1,700 | $1,716 |
| Net Income | -$7.7M | -$14.3M | -$15.4M | -$15.0M | -$20.8M |
| Diluted EPS | -$52.92 | — | -$51.24 | -$45.08 | -$21.58 |
Indaptus Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$3.0M | -$8.1M | -$2.5M | -$1.8M |
| Diluted EPS | -$2.98 | -$8.40 | -$0.23 | -$0.02 |
Indaptus Therapeutics Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $39.1M | $9.6M | $13.4M | $5.8M | $8.5M |
| Current Assets | $40.4M | $27.2M | $14.0M | $6.6M | $9.3M |
| Total Assets | $40.6M | $28.1M | $14.9M | $7.3M | $9.3M |
| Current Liabilities | $4.6M | $3.4M | $2.8M | $3.4M | $6.2M |
| Total Liabilities | $4.7M | $3.4M | $2.8M | $3.4M | $6.2M |
| Shareholders' Equity | $35.9M | $24.6M | $12.1M | $3.9M | $3.2M |
Indaptus Therapeutics Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$11.3M | -$13.1M | -$13.4M | -$12.3M | -$14.8M |
| Cash From Investing | $447,746 | -$16.4M | $17.1M | — | — |
| Cash From Financing | $48.3M | — | — | $4.7M | $17.5M |
| Free Cash Flow | -$11.3M | -$13.1M | -$13.4M | -$12.3M | -$14.8M |
Figures from Indaptus Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Indaptus Therapeutics financials page for every line item.
Indaptus Therapeutics Company Profile
| Ticker | INDP |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | New York, New York |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001857044 |
Frequently Asked Questions
What was Indaptus Therapeutics' revenue in fiscal 2025?
Indaptus Therapeutics (INDP) reported revenue of $0 for fiscal 2025.
What is Indaptus Therapeutics' annual revenue history?
Indaptus Therapeutics' annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Indaptus Therapeutics' net income in fiscal 2025?
Indaptus Therapeutics reported net income of -$20.8M for fiscal 2025.
What was Indaptus Therapeutics' earnings per share (EPS) in fiscal 2025?
Indaptus Therapeutics' diluted EPS was -$21.58 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Indaptus Therapeutics generate in fiscal 2025?
Indaptus Therapeutics generated -$14.8M of free cash flow in fiscal 2025.
What was Indaptus Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Indaptus Therapeutics reported revenue of $0.
How many shares of Indaptus Therapeutics are outstanding?
Indaptus Therapeutics reported a weighted average of 116.1 million basic shares outstanding in 2026 Q2.
What is Indaptus Therapeutics' market cap?
Based on its latest closing price, Indaptus Therapeutics (INDP) has a market capitalization of about $277.6M.
When does Indaptus Therapeutics' fiscal year end?
Indaptus Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Indaptus Therapeutics headquartered?
Indaptus Therapeutics lists its business address in New York, New York in its SEC filings.